vs
SUTRO BIOPHARMA, INC.（STRO）与泛美白银（USAS）财务数据对比。点击上方公司名可切换其他公司
泛美白银的季度营收约是SUTRO BIOPHARMA, INC.的1.6倍（$19.1M vs $11.6M），SUTRO BIOPHARMA, INC.同比增速更快（-21.4% vs -28.0%）
Sutro Biopharma是一家上市生物科技公司，总部位于加州南旧金山，专注于临床阶段药物的研发、开发与生产。公司依托自主专有的无细胞蛋白质合成平台，结合蛋白质工程与理性设计技术开发肿瘤治疗药物。公司2003年成立时名为Fundamental Applied Biology，2009年改用现名。
泛美白银是一家总部位于加拿大的矿业企业，业务布局集中在拉丁美洲，在墨西哥、秘鲁、玻利维亚、阿根廷多国持有运营矿山及其他矿产开发项目，是美洲地区重要的贵金属开采企业。
STRO vs USAS — 直观对比
营收规模更大
USAS
是对方的1.6倍
$11.6M
营收增速更快
STRO
高出6.7%
-28.0%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $11.6M | $19.1M |
| 净利润 | — | $-15.7M |
| 毛利率 | — | 34.2% |
| 营业利润率 | — | — |
| 净利率 | — | -82.3% |
| 营收同比 | -21.4% | -28.0% |
| 净利润同比 | 35.4% | 2.8% |
| 每股收益（稀释后） | — | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收STROUSAS
| Q4 25 | $11.6M | — | ||
| Q3 25 | $9.7M | $19.1M | ||
| Q2 25 | $63.7M | — | ||
| Q1 25 | $17.4M | — | ||
| Q4 24 | $14.8M | — | ||
| Q3 24 | $8.5M | $26.5M | ||
| Q2 24 | $25.7M | — | ||
| Q1 24 | $13.0M | — |
净利润STROUSAS
| Q4 25 | — | — | ||
| Q3 25 | $-56.9M | $-15.7M | ||
| Q2 25 | $-11.5M | — | ||
| Q1 25 | $-76.0M | — | ||
| Q4 24 | $-72.4M | — | ||
| Q3 24 | $-48.8M | $-16.2M | ||
| Q2 24 | $-48.0M | — | ||
| Q1 24 | $-58.2M | — |
毛利率STROUSAS
| Q4 25 | — | — | ||
| Q3 25 | — | 34.2% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 23.6% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
营业利润率STROUSAS
| Q4 25 | — | — | ||
| Q3 25 | -499.9% | — | ||
| Q2 25 | -5.2% | — | ||
| Q1 25 | -393.8% | — | ||
| Q4 24 | -440.7% | — | ||
| Q3 24 | -797.2% | — | ||
| Q2 24 | -189.4% | — | ||
| Q1 24 | -435.0% | — |
净利率STROUSAS
| Q4 25 | — | — | ||
| Q3 25 | -586.6% | -82.3% | ||
| Q2 25 | -18.0% | — | ||
| Q1 25 | -436.6% | — | ||
| Q4 24 | -489.2% | — | ||
| Q3 24 | -572.6% | -60.9% | ||
| Q2 24 | -186.8% | — | ||
| Q1 24 | -447.5% | — |
每股收益（稀释后）STROUSAS
| Q4 25 | — | — | ||
| Q3 25 | $-0.67 | — | ||
| Q2 25 | $-0.14 | — | ||
| Q1 25 | $-0.91 | — | ||
| Q4 24 | $-27.63 | — | ||
| Q3 24 | $-0.59 | — | ||
| Q2 24 | $-0.59 | — | ||
| Q1 24 | $-0.59 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $141.4M | $39.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-132.5M | $50.2M |
| 总资产 | $173.8M | $234.7M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资STROUSAS
| Q4 25 | $141.4M | — | ||
| Q3 25 | $167.6M | $39.1M | ||
| Q2 25 | $205.1M | — | ||
| Q1 25 | $249.0M | — | ||
| Q4 24 | $316.9M | — | ||
| Q3 24 | $388.3M | — | ||
| Q2 24 | $375.6M | — | ||
| Q1 24 | $267.6M | — |
股东权益STROUSAS
| Q4 25 | $-132.5M | — | ||
| Q3 25 | $-87.3M | $50.2M | ||
| Q2 25 | $-32.1M | — | ||
| Q1 25 | $-25.8M | — | ||
| Q4 24 | $44.6M | — | ||
| Q3 24 | $111.2M | $53.1M | ||
| Q2 24 | $152.2M | — | ||
| Q1 24 | $98.0M | — |
总资产STROUSAS
| Q4 25 | $173.8M | — | ||
| Q3 25 | $209.7M | $234.7M | ||
| Q2 25 | $262.4M | — | ||
| Q1 25 | $321.4M | — | ||
| Q4 24 | $387.2M | — | ||
| Q3 24 | $451.8M | — | ||
| Q2 24 | $489.0M | — | ||
| Q1 24 | $403.4M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-177.2M | $-12.5M |
| 自由现金流经营现金流 - 资本支出 | — | $-41.3M |
| 自由现金流率自由现金流/营收 | — | -216.5% |
| 资本支出强度资本支出/营收 | — | 150.8% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流STROUSAS
| Q4 25 | $-177.2M | — | ||
| Q3 25 | $-38.2M | $-12.5M | ||
| Q2 25 | $-44.7M | — | ||
| Q1 25 | $-67.9M | — | ||
| Q4 24 | $-71.7M | — | ||
| Q3 24 | $-64.5M | $2.4M | ||
| Q2 24 | $9.5M | — | ||
| Q1 24 | $-64.7M | — |
自由现金流STROUSAS
| Q4 25 | — | — | ||
| Q3 25 | — | $-41.3M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-11.2M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
自由现金流率STROUSAS
| Q4 25 | — | — | ||
| Q3 25 | — | -216.5% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -42.2% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资本支出强度STROUSAS
| Q4 25 | — | — | ||
| Q3 25 | — | 150.8% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 51.2% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
